BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

...veteran of the global BD team of Merck & Co. Inc....
BioCentury | Apr 15, 2021
Product Development

Merck’s COVID-19 arsenal continues to dwindle as pharma scraps fusion protein from OncoImmune takeout

...By Paul Bonanos, Associate Editor Merck’s roster of COVID-19 countermeasures gained via deals continued to shrink...
...HHS and the Department of Defense.A Merck spokesperson declined to tell BioCentury how much money Merck...
...patients following stem cell transplantation. Merck’s spokesperson said that trial is unaffected by Thursday’s decision.Since Merck’s...
BioCentury | Apr 15, 2021
Politics, Policy & Law

Georgia biotech leaders support voting rights, resist calls to shun their state

...statement published Wednesday in The New York Times that Kenneth Frazier, chairman and CEO of Merck & Co. Inc....
BioCentury | Apr 15, 2021
Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

...study, INDUCE-4, was evaluating feladilimab vs. placebo in combination with pembrolizumab and chemotherapy. GSK is partnered with Merck & Co. Inc....
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

...veteran of the global BD team of Merck & Co. Inc....
BioCentury | Apr 8, 2021
Management Tracks

Fineberg to lead SVB Leerink’s structured finance group; plus Gimv, Syncona, Tessera, NKGen and more

...as partner. Jurgeit was a partner at Lundbeckfonden Emerge and previously served as director at Merck...
BioCentury | Apr 7, 2021
Deals

Radioligand target deal with Novartis expands Artios’ runway and remit

...among the three potential targets.The new deal comes about four months after Artios partnered with Merck...
BioCentury | Apr 7, 2021
Distillery Therapeutics

A targeted CDK12 degrader for ALL

...human T cell ALL lines, the compound reduced proliferation and synergized with PARP inhibitor Lynparza olaparib.Merck & Co. Inc....
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

...as CEO-partner and became CEO of portfolio company Generate Biomedicines Inc. Nally, an 18-year veteran of Merck & Co. Inc....
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...at the Merck Research Laboratories unit of Merck & Co. Inc....
Items per page:
1 - 10 of 10366
BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

...veteran of the global BD team of Merck & Co. Inc....
BioCentury | Apr 15, 2021
Product Development

Merck’s COVID-19 arsenal continues to dwindle as pharma scraps fusion protein from OncoImmune takeout

...By Paul Bonanos, Associate Editor Merck’s roster of COVID-19 countermeasures gained via deals continued to shrink...
...HHS and the Department of Defense.A Merck spokesperson declined to tell BioCentury how much money Merck...
...patients following stem cell transplantation. Merck’s spokesperson said that trial is unaffected by Thursday’s decision.Since Merck’s...
BioCentury | Apr 15, 2021
Politics, Policy & Law

Georgia biotech leaders support voting rights, resist calls to shun their state

...statement published Wednesday in The New York Times that Kenneth Frazier, chairman and CEO of Merck & Co. Inc....
BioCentury | Apr 15, 2021
Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

...study, INDUCE-4, was evaluating feladilimab vs. placebo in combination with pembrolizumab and chemotherapy. GSK is partnered with Merck & Co. Inc....
BioCentury | Apr 13, 2021
Regulation

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

...veteran of the global BD team of Merck & Co. Inc....
BioCentury | Apr 8, 2021
Management Tracks

Fineberg to lead SVB Leerink’s structured finance group; plus Gimv, Syncona, Tessera, NKGen and more

...as partner. Jurgeit was a partner at Lundbeckfonden Emerge and previously served as director at Merck...
BioCentury | Apr 7, 2021
Deals

Radioligand target deal with Novartis expands Artios’ runway and remit

...among the three potential targets.The new deal comes about four months after Artios partnered with Merck...
BioCentury | Apr 7, 2021
Distillery Therapeutics

A targeted CDK12 degrader for ALL

...human T cell ALL lines, the compound reduced proliferation and synergized with PARP inhibitor Lynparza olaparib.Merck & Co. Inc....
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

...as CEO-partner and became CEO of portfolio company Generate Biomedicines Inc. Nally, an 18-year veteran of Merck & Co. Inc....
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...at the Merck Research Laboratories unit of Merck & Co. Inc....
Items per page:
1 - 10 of 10366